The PLUTO trial aims to contribute to the worldwide search for a functional cure of HIV. One the strategies ("shock and kill' strategy) aims to reverse the HIV-reservoir from latency by increasing cell-associated HIV-RNA, which will lead to increased antigen presentation, trigger immune recognition, and facilitate the elimination of reservoir cells. Participants of the trial are adults with HIV with undetectable viral load that are able to give informed consent to participate in the trial, in total 30 patients will be recruited. The investigational medical compounds in this trial are topiramate, lenalidomide and pyrimethamine, which will be combined. These are all licensed drugs for other conditions.
The study consists of two phases. In phase I participants will receive a single dose of the IMPs, as combination therapy. Sampling will be performed before, during and after medical treatment to evaluate latency reversal and safety endpoints. In phase II, participants will receive the combination of IMPs which is the most potent and within safety limits selected from phase I during a four-week treatment. Sampling will take place on a weekly basis to assess latency reversal, reservoir reduction and safety.
Participants will be recruited from the Erasmus MC, Amsterdam university Medical Center, Radboud University Medical Center and the University Medical Center Utrecht.

Start Date01 Apr 2026

Sponsor / Collaborator-

NCT06240520

/ Unknown statusPhase 1/2IIT

Optimizing Reversal of HIV Latency With Combination Therapy (Pyrimethamine, Lenalidomide, Panobinostat)

The ORBIT trial is part of a worldwide search for a functional cure of HIV. One such cure strategy aims to reverse HIV in the reservoir from latency by increasing cell-associated HIV-RNA, which will lead to increased antigen presentation, trigger immune recognition, and facilitate the elimination of reservoir cells (so-called 'shock and kill' approach to HIV cure). Participants of the trial are adults with HIV with undetectable viral load that are able to give informed consent to participate in the trial, in total 49 patients will be recruited. The investigational medical compounds in this trial are panobinostat, lenalidomide and pyrimethamine. These are all licensed drugs for other conditions. Participants of this trial will receive a single dose of the IMPs, either as monotherapy or as combination therapy. Sampling will be performed before, during and after medical treatment to evaluate latency reversal, reservoir reduction and safety endpoints. Patients will be recruited from the Erasmus MC, Amsterdam university Medical Center and the University Medical Center Utrecht.

Start Date01 Apr 2024

Sponsor / Collaborator

Erasmus MC

NCT05678348

/ CompletedEarly Phase 1IIT

Early Phase I Window of Opportunity Biomarker and Safety Trial to Test Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated, Locally Advanced Head and Neck Squamous Cell Carcinoma

NRF2 activation, observed in up to 40% of head and neck squamous cell carcinoma (HNSCC) tumors, plays a critical role in tumor progression, metastasis, and radiation therapy resistance. The investigators have recently discovered that pyrimethamine (PYR) and its analogs have an inhibitory effect on NRF2 activity in vitro and in mouse models via inhibition of dihydrofolate reductase (DHFR).
Pyrimethamine is an established drug that has been used for decades for treatment of protozoan infections and malaria. A growing body of research shows that it has potential antitumor activity, however its activity on growing human tumors has not been previously studied. The primary efficacy goal of this study is to evaluate the activity of pyrimethamine on human tumors as demonstrated by inhibition of DHFR and downregulation of NRF2 pathway activity. On-target inhibition of DHFR by pyrimethamine results in the stabilization and increased protein expression of human DHFR.
The primary efficacy hypothesis of this study is that treatment with pyrimethamine will result in a 50% increase in DHFR protein within the tumor cells as measured by quantitative western blot analysis. Secondarily, among those tumors classified as NRF2-active on pre-treatment biopsy, the investigators hypothesize there will be a 50% reduction in NRF2 activity as measured by SureQuant targeted proteomic analysis.

Start Date03 Aug 2023

Sponsor / Collaborator

Washington University School of Medicine

[+1]

100 Clinical Results associated with Pyrimethamine

100 Translational Medicine associated with Pyrimethamine

100 Patents (Medical) associated with Pyrimethamine

5,399

Literatures (Medical) associated with Pyrimethamine

01 Mar 2026·ACTA TROPICA

Acetazolamide as a novel therapeutic agent against acute experimental toxoplasmosis: Insights into carbonic anhydrase inhibition

Article

Author: Hassan, Aceel Y ; Diab, Hala ; El Skhawy, Nahla ; Hassan, Sarah Ahmed

Although the current therapeutic regimens for acute toxoplasmosis, most commonly a combination of pyrimethamine and sulfadiazine, are still considered the standard of care, they are associated with numerous drawbacks, such as bone marrow suppression, and hepatotoxicity. Given these challenges, there is an urgent need to explore and find safer and more effective therapeutic alternatives. Acetazolamide has been widely used in clinical practice for non-infectious illnesses. Lately, increasing attention has been directed toward its repurposing as an antiparasitic agent. Thirty-six mice were infected with Toxoplasma gondii (RH strain) tachyzoites, and divided into three groups: non-treated group, Acetazolamide-treated group and Septrin- treated group. In the present study, the anti - Toxoplasma efficacy of Acetazolamide was assessed in comparison to Septrin using parasitological, ultrastructural, biochemical, immunological, and histopathological studies. Treatment with Acetazolamide significantly prolonged the mice's survival time and reduced tachyzoites count with percentages of reduction of 83.12% and 79.84 % in the peritoneal fluids and hepatic impression smears, respectively. Furthermore, Acetazolamide has dramatically altered the ultrastructure of the tachyzoites, decreased the liver and kidney malondialdehyde levels and suppressed serum cytokines (tumor necrosis factor alpha and interleukin-1β). Histopathological examination of hepatic and renal tissue sections showed amelioration of parenchymal inflammation and scanty parasite. In conclusion, Acetazolamide demonstrated a significant promise as a therapeutic agent for combating acute murine toxoplasmosis with anti-inflammatory and antioxidant effects.

01 Jan 2026·BMJ Global Health

Effectiveness of antenatal care delivery of intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine in the context of an integrated strategy with seasonal malaria chemoprevention in Mali and Burkina Faso

Article

Author: Biébo, Bihoun ; Kayentao, Kassoum ; Briand, Valérie ; Dembele, Mahamadou ; Tinto, Halidou ; Bognini, Joel D ; Diarra, Samba ; Huyen Ton Nu Nguyet, Minh ; Rouamba, Toussaint ; Hill, Jenny ; Coulibaly, Oumou ; Worrall, Eve ; Koita, Kadiatou

Background:

To improve uptake of intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP), a cluster-randomised implementation trial of ‘integrated IPTp-SP delivery’ through seasonal malaria chemoprevention (SMC) alongside antenatal care (ANC) was conducted in Mali and Burkina Faso. This nested study assessed ANC provider acceptability and feasibility of the integrated strategy and whether the training they received as part of the intervention (‘enhanced facilities’) improved IPTp-SP delivery effectiveness.

Methods:

A cross-sectional survey was conducted in 20 trial facilities in each country (10 intervention/10 control) from November 2023 to January 2024, involving ANC exit interviews with pregnant women, facility audits and structured interviews with ANC providers. The primary outcome was the proportion of eligible pregnant women receiving IPTp-SP by directly observed therapy (DOT). Predictors of receiving IPTp-SP by DOT were estimated using mixed model logistic regression. ANC provider attitudes towards the integrated strategy were assessed using Likert scales.

Results:

In Mali, 240 and 297 of 703 women interviewed were eligible for SP in the intervention and control facilities, respectively, and 323 and 334 of 709 women, respectively, interviewed in Burkina Faso. Delivery effectiveness of IPTp-SP was higher in the enhanced facilities in both Mali (79.2% (95% CI 74.0% to 84.3%) vs 68.7% (95% CI 63.4% to 73.9%), p=0.006) and Burkina Faso (52.3% (95% CI 46.9% to 57.8%) vs 28.7% (95% CI 23.9% to 33.6%), p<0.0001). Predictors of receiving IPTp-SP by DOT included attending a routine ANC visit in Mali, and gestational age, multiparity and a routine ANC visit in Burkina Faso. ANC providers interviewed in Mali (44) and Burkina Faso (41) thought that IPTp-SP delivery through SMC increased ANC attendance and reduced malaria cases, and that it was feasible and acceptable.

Conclusions:

ANC provider training improved IPTp-SP delivery effectiveness, showing greater impact in Mali than in Burkina Faso. ANC providers found the integrated IPTp-SP strategy through ANC and SMC acceptable and feasible.

01 Jan 2026·Translational Oncology

The PI3K pathway is a downstream effector of NRF2 activation in the esophagus

Article

Author: Xiong, Zhaohui ; Paiboonrungruang, Chorlada ; Chen, Xiaoxin ; Spitz, Francis ; Bui-Linh, Candice ; Subramaniyan, Boopathi ; Li, Yahui

Mutations in nuclear factor erythroid 2-related factor 2 (NFE2L2 or NRF2) occur in 10-22 % of esophageal squamous cell carcinoma (ESCC) cases and result in NRF2 activation, promoting tumor progression, and therapeutic resistance. Although previous studies suggested a link between NRF2 and kinases, specific kinases responsive to NRF2 activation remain to be fully identified. Using protein phosphorylation profiling and kinase activity profiling, we identified phosphatidylinositol 3-kinase (PI3K) pathway as a downstream effector in NRF2^W24C-KYSE70 cells compared to isogenic NRF2^null-KYSE70 cells. AREG, pEGFR, PIK3CA, pAKT, p-S6, and p-PTEN were downregulated in NRF2 deficient cells. Notably, NRF2 deficiency sensitized ESCC cells to EGFR, PIK3CA, and AKT inhibitors. Co-treatment with Alpelisib (a PIK3CA inhibitor) and Pyrimethamine (an NRF2 inhibitor) synergistically suppressed the growth of NRF2^W24C-KYSE70 and NRF2^D77V-KYSE180 cells. In vivo, NRF2 activation in the esophageal epithelium of Keap1^-/- and Sox2CreER;LSL-Nrf2^E79Q/+ mice resulted in upregulation of pAKT, p-mTOR, and pS6. In human ESCC tissues, expression of pNRF2 (an active form of NRF2) was positively associated with that of pAKT and p-mTOR. Furthermore, co-treatment with Pyrimethamine and Alpelisib significantly inhibited hyperproliferation and hyperkeratinization in the esophageal epithelium of Sox2CreER;LSL-Nrf2^E79Q/+mice. Together, our data demonstrates the PI3K pathway as a downstream effector of NRF2 activation in the esophagus, and co-targeting of NRF2 and the PI3K pathway may offer a promising therapeutic strategy for NRF2^Mut ESCC.

116

News (Medical) associated with Pyrimethamine

23 Jun 2025

·www.globenewswire.com

Optime Care Partners with Tilde Sciences as Exclusive Specialty Pharmacy Provider for Vecamyl

ST. LOUIS, June 23, 2025 (GLOBE NEWSWIRE) -- Optime Care, AscellaHealth’s Specialty Pharmacy, is pleased to announce an expanded partnership with Tilde Sciences LLC (“Tilde”), effective June 23, 2025. Under this arrangement, Optime Care will serve as the exclusive specialty pharmacy provider for dispensing the newly FDA-approved and relaunched Vecamyl (mecamylamine) 2.5 mg tablets to patients. Tilde, a pharmaceutical company focused on developing and commercializing treatments for rare diseases with significant unmet needs, selected Optime Care for its proven track record in program continuity, prior experience with Vecamyl® and Daraprim® and expertise in managing small, specialized patient populations. “Our continued and expanded relationship with Tilde demonstrates their confidence in Optime Care’s ability to meet the needs of specialty patient populations through highly-personalized programs, tailored patient communications and educational support throughout the treatment journey,” says Bill Bertetto, general manager, Optime Care. “Tilde values the expertise of our dedicated Patient Care Teams who have a deep understanding of complex disease states and provide guidance every step of the way. These specialists help enhance patient access to essential therapies, streamline care coordination and ensure financial assistance is available to those in need.” Leveraging innovative, proprietary technology platforms and patient engagement tools, Optime Care’s expert teams, including specially trained Patient Care Coordinators, deliver end-to-end solutions that drive improved individual outcomes and exceptional compliance rates. Akeel Mithani, president of Tilde states, “Optime Care is a trusted partner, reliably ensuring that patients with rare, complex diseases receive their medications on time and wherever needed. Over a year ago, we made a great decision to partner with Optime Care and we continue to rely on their unmatched expertise. Their teams consistently demonstrate a shared commitment to care for vulnerable specialty patients. It has been a gratifying experience working with Optime Care and we look forward to further collaboration to improve the clinical outcomes and quality of life for the patients we serve.” Vecamyl (mecamylamine) had been unavailable for new patients following its acquisition from the previous owner. The Company has since partnered with new supply chain providers to address and resolve the prior supply challenges. Today, the Company is pleased to announce that Vecamyl is now available through Tilde’s comprehensive patient support program, Tilde Total Care. Questions pertaining to access and affordability of Vecamyl (mecamylamine) should be directed to 1-877-794-0008. About Optime CareOptime Care, Inc., AscellaHealth’s Specialty Pharmacy, is a nationally recognized specialty pharmacy, distribution and patient management organization offering a suite of comprehensive services tailored to maximize therapeutic opportunities for the treatment of orphan and rare disorders. The executive team has partnered in the launch and management of over 40 orphan products and programs while consistently implementing the best brand services for the community. Optime Care has dual-accreditation from the Utilization Review Accreditation Commission (URAC) for compliance with specialty pharmacy and the Accreditation Commission for Health Care (ACHC) for specialty pharmacy services that demonstrate a commitment to providing quality care and services to consumers. Visit: https://www.optimecare.com/*Optime Care is wholly owned by Innovative Specialty Solutions, LLC, an affiliate of AscellaHealth, LLC. About Tilde Tilde Sciences is a United States based biopharmaceutical company specializing in the development and commercialization of specialty pharmaceuticals tailored for rare diseases with significant unmet needs. For more information visit https://www.tildesciences.com/ About VECAMYL®INDICATION VECAMYL® (mecamylamine HCI tablets USP) 2.5 mg is indicated for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension. IMPORTANT SAFETY INFORMATION VECAMYL® should not be used in people with mild, moderate high blood pressure that can suddenly fluctuate at different times of the day. You should not use VECAMYL if you have a heart condition that reduces the flow of blood to the heart or had a recent heart attack. Patients with a certain type of abnormal kidney function should use VECAMYL with caution, and those with increased levels of urea in their blood should not use VECAMYL. In general, it is not advised to use VECAMYL if you are receiving antibiotics and sulfonamides. Do not use VECAMYL if you have glaucoma. Do not use VECAMYL if your healthcare provider indicated you have organic pyloric stenosis. You should not use VECAMYL if you previously had a serious allergic reaction to mecamylamine hydrochloride (the medicine in VECAMYL). VECAMYL should be used with caution if you have a disease that reduces blood flow to the heart and brain, such as arteriosclerosis, or have had a recent stroke. It is important before using VECAMYL that the function of your kidneys and heart are evaluated by your healthcare professional. With certain diseases that reduce blood flow to the kidneys, brain, or heart, some people may experience worsening of symptoms due to reduction of blood pressure with VECAMYL therapy. Also, discuss with your healthcare provider if you have bladder or urinary problems as VECAMYL can make it difficult to completely empty one's bladder. VECAMYL may cause dizziness, lightheadedness, or fainting, especially when rising from a sitting or lying position. This effect may be increased by alcoholic beverages, exercise, or during hot weather. Rising slowly may help prevent these effects. Tell your healthcare provider if you experience tremors, jerky involuntary movements, mental aberrations, or convulsions after taking VECAMYL. Immediately tell your healthcare provider if you experience loose bowel movements with stomach bloating and decreased rumbling. Use VECAMYL as directed by your healthcare provider. The information of this website should not take place of talking to your doctor. If you have any questions about your condition or if you would like more information on VECAMYL, talk to your doctor or pharmacist. Only you and your doctor can decide if VECAMYL is right for you. Do not stop using VECAMYL unless told so by your healthcare provider because suddenly stopping the drug may cause high blood pressure to return. A sudden rise in blood pressure may cause stroke or heart failure. However, the effects of VECAMYL may last from hours to days after one stops using the drug. For more information about VECAMYL, including additional side effects, please see the Full Prescribing Information for VECAMYL. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/Safety/MedWatch/default.htm or call 1-800-FDA-1088. You may also report an adverse event by calling (800) 769-8874. This press release was published by a CLEAR® Verified individual. Media: Caroline Chambers CPR Communications cchambers@cpronline.com 201.641.1911 x 21

AcquisitionDrug Approval

07 Oct 2024

·endpts.com

Supreme Court declines to review patent battle over inhalation powder Yutrepia

Liquidia’s stock $LQDA rose about 10% on Monday following a win in the US Supreme Court for its treprostinil inhalation powder Yutrepia. Liquidia has been fighting United Therapeutics over competing drugs in various court battles over the last several years. The FDA handed down a tentative approval for Yutrepia in August, but also said that Yutrepia won’t receive final approval until Tyvaso’s regulatory exclusivity is over in May 2025. Liquidia’s drug is approved to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). “United Therapeutics has pulled out all the stops to prevent our product from coming to market at all. And I think with this decision, this product is now going to come to market,” Liquidia’s chief business officer Jason Adair told Endpoints News . “I think that’s a big milestone for us as a company, is that this product is going to come to market when the regulatory exclusivity expires, if not earlier.” In an announcement , Liquidia said the court rejected United Therapeutics’ petition which requested permission to appeal prior decisions in Liquidia’s favor that found that all claims of one of United’s patents are unpatentable. The company added in its announcement that there are currently no patents preventing final FDA approval of Yutrepia, although a trial over another patent is scheduled for June 2025. Thanks to the Supreme Court, the 2022 decision by the Patent Trial and Appeal Board, which invalidated United’s claims of patent infringement — and a decision by the US Court of Appeals for the Federal Circuit in 2023 that upheld the board’s decision — are now final and can’t be appealed. Jeffs wrote in a statement that that patent is now unenforceable and Liquidia will “fight for the earliest possible launch” of Yutrepia. Also on Monday, SCOTUS declined to hear a case involving former pharma executive Martin Shkreli, as he sought to reverse a $65 million payment he owes following allegations around his raising the price of the HIV drug Daraprim. Editor’s note: This story has been updated to correctly identify Jason Adair’s quote.

Drug ApprovalPatent InfringementPatent Expiration

13 Jan 2024

·www.sciencedaily.com

African women living with HIV have an effective option to prevent malaria during pregnancy

In women living with HIV, preventive treatment with DHA-PPQ is a safe and effective strategy to prevent malaria during pregnancy, according to the final results of the MAMAH clinical trial. In women living with HIV, preventive treatment with DHA-PPQ is a safe and effective strategy to prevent malaria during pregnancy, according to the final results of MAMAH, a clinical trial funded by the European & Developing Countries Clinical Trials Partnership (EDCTP) and coordinated by the Barcelona Institute for Global Health (ISGlobal), an institution supported by "la Caixa" Foundation. The study, published in the Lancet Infectious Diseases, could help protect the health of the estimated one million pregnant women who suffer from a double infection with malaria and HIV every year. Pregnant women are particularly vulnerable to malaria infection. Hence the recommendation to offer preventive treatment (IPTp) based on sulphadoxine and pyrimethamine (SP) to pregnant women living in malaria-endemic areas. The problem is that these drugs are incompatible with co-trimoxazole (CTX), an antibiotic given to people with HIV to prevent bacterial infections. "This means that the population most vulnerable to malaria infection and its consequences, namely pregnant women living with HIV, are also the least protected," explains ISGlobal researcher Raquel González, technical coordinator of the MAMAH project, led by Clara Menéndez, director of ISGlobal's Maternal, Child and Reproductive Health Initiative. The aim of the project was to evaluate the safety and efficacy of two other drugs: dihydroartemisinin and piperaquine (DHA-PPQ) to prevent malaria during pregnancy in women living with HIV. The research team conducted the trial in Gabon and Mozambique with more than 600 pregnant women taking CTX in addition to antiretroviral treatment for HIV. One group of pregnant women received DHA-PPQ and the other group received a placebo. Lower risk of malaria infection and disease Although there was no significant difference in malaria infection at the time of delivery, women in the DHA-PPQ group had a significantly lower risk of developing clinical malaria throughout pregnancy (almost eight times lower than the placebo group) and also a lower risk (almost half) of becoming infected. DHA-PPQ was effective in women taking different antiretroviral treatments. No serious side effects were observed, and DHA-PPQ had no effect on mother-to-child transmission of HIV. "We show that preventive treatment with DHA-PPQ is effective even in low malaria transmission settings," says Gonzalez. "Adding this strategy to malaria control tools could significantly improve the health of thousands of mothers and their babies, especially in sub-Saharan Africa, a region where an estimated one million women living with HIV are infected with malaria during pregnancy every year," she adds. "We congratulate the MAMAH team on these important results in the field of malaria research, and, in particular, in providing better health to pregnant women living with HIV in malaria-endemic areas," says Montserrat Blázquez-Domingo, EDCTP Senior Project Officer. "This study underlines the value of collaborative research that EDCTP supports and our focus on priority infectious disease affecting sub-Saharan Africa in populations often excluded from clinical trials -- such as pregnant women." The MAMAH study is part of the EDCTP2 Programme supported by the European Union (grant number RIA2016MC-1613-MAMAH).

Clinical ResultClinical Study

100 Deals associated with Pyrimethamine

External Link

KEGG	Wiki	ATC	Drug Bank
D00488	Pyrimethamine	P01BD01	DB00205

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Infectious Diseases	Australia	Arrotex Pharmaceuticals Pty Ltd.	11 Nov 2003
Acute Malaria	United States	TILDE SCIENCES LLC	23 Jan 1953
Malaria	United States	TILDE SCIENCES LLC	23 Jan 1953
Toxoplasmosis	United States	TILDE SCIENCES LLC	23 Jan 1953

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 1	United States	TILDE SCIENCES LLC	03 Aug 2023
Esophageal Squamous Cell Carcinoma	Preclinical	United States	Coriell Institute for Medical Research	27 Apr 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01066663 (CTgov)	Phase 1/2	Recurrent Chronic Lymphoid Leukemia \| Small Lymphocytic Lymphoma	20	pyrimethamine (DL1: Pyrimethamine 12.5 mg)	wxjuwmccvd = xquihwjauj urnsomwehi (rqbvswwnpc, lhgxmzrtcz - ilpdfiigqz) View more	-	01 Dec 2022
				pyrimethamine (DL2: Pyrimethamine 25 mg)	wxjuwmccvd = cscxcwlrhd urnsomwehi (rqbvswwnpc, wbuiqfpbeu - aurtdllxvx) View more
NCT03952650 (CTgov)	Phase 1/2	Malaria	252	PYR (1a - Pilot/Safety: Dosing Interval on Days: 1)	vwnsoqfxhp = qvtmlnytka dzdpzpnfgy (vuvjgczsgq, dfomcklrog - lwwvcgyqgm) View more	-	12 Jul 2022
				PYR (2a - Pilot/Safety: Dosing Interval on Days: 1)	vwnsoqfxhp = yiofjtoaez dzdpzpnfgy (vuvjgczsgq, dzmmeihudh - vzewygtlhb) View more
NCT03083847 \| NCT02511054 (Pubmed \| Nature)	Phase 1	Malaria	-	PfSPZ malaria vaccines (Sanaria PfSPZ-CVac(PYR))	ddatxjnhyo(ilviywcpdf) = brbngvpkwq bseanwpdzp (yokarixmxx )	-	08 Jul 2021
				PfSPZ-CVac(CQ)	ddatxjnhyo(ilviywcpdf) = obfgauxalw bseanwpdzp (yokarixmxx )
NCT01083667 (CTgov)	Phase 1/2	Amyotrophic Lateral Sclerosis	32	Pyrimethamine	udjykvlchi(caefkeasoc) = ppdgrvcvdx ubzhawsonv (bcshyhirpi, vvjcgijmbb - tkjrnbcxbi) View more	-	19 Jun 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis